Latest Biotechnology News

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.

Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.

Zoono Group has boosted its cash receipts by NZ$333,000 this quarter, driven by initial orders worth NZ$585,000 in its fresh food shelf-life extension sector. Despite operating losses, the company expects to sustain operations through signed contracts and inventory.

Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.